Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Support Care Cancer
; 26(4): 1273-1279, 2018 Apr.
Article
in En
| MEDLINE
| ID: mdl-29090385
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vomiting
/
Colorectal Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Antiemetics
/
Nausea
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Support Care Cancer
Journal subject:
NEOPLASIAS
/
SERVICOS DE SAUDE
Year:
2018
Type:
Article
Affiliation country:
United States